Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Gets Nasdaq Non-Compliance Notice

NEW YORK — Centogene said last week that it has been notified by Nasdaq about its noncompliance with the stock exchange's $1 minimum bid price listing requirement.

According to the Rostock, Germany-based company, which uses genomic and other data to develop diagnostics and support drug discovery for rare diseases, its shares have traded below the $1 threshold for 30 consecutive business days. As a result, Centogene has until June 12, 2023, to regain compliance with the listing requirement, during which time the stock will continue to trade on the Nasdaq.

Centogene has not announced any financial results since July, when it reported its earnings for the first quarter of 2022.

On Friday, shares of Centogene closed at $.9201.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.